Inspire Medical Systems Q1 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: seekingalpha
- Earnings Beat: Inspire Medical Systems reported a Q1 non-GAAP EPS of $0.10, exceeding expectations by $0.36, indicating strong profitability and boosting investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $204.58 million, a 1.6% year-over-year increase, surpassing market expectations by $4.55 million, reflecting stable growth and sustained product demand.
- 2026 Guidance Revision: Inspire revised its 2026 revenue outlook to a range of $825 million to $875 million, representing a decline of 4% to 10% compared to 2025, highlighting challenges in the market environment.
- Profitability Outlook: The company expects an adjusted operating margin of 2% to 4% for 2026, with diluted EPS projected between $0.07 and $0.62, and adjusted diluted EPS ranging from $0.75 to $1.25, indicating a cautious approach to profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSP
Wall Street analysts forecast INSP stock price to rise
19 Analyst Rating
13 Buy
6 Hold
0 Sell
Moderate Buy
Current: 50.080
Low
91.00
Averages
145.31
High
180.00
Current: 50.080
Low
91.00
Averages
145.31
High
180.00
About INSP
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspire Medical Systems Announces Q2 2026 Earnings Release Date
- Earnings Release Schedule: Inspire Medical Systems will release its financial results for Q2 2026 after market close on August 3, with management hosting a conference call at 5:00 PM ET to discuss the results and recent business developments, ensuring investors stay informed about company updates.
- Conference Call Participation: Investors can access the call via the webcast on the company's Investor Relations page, and those wishing to ask questions must register in advance to receive dial-in details and a unique access code, ensuring connection at least 10 minutes before the call starts.
- Replay Availability: A replay of the call will be available on the company's Investor Relations website approximately two hours after the event, archived for two weeks, allowing investors who could not attend live to catch up on the discussion.
- Company Overview: Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea, with its proprietary Inspire therapy being the first FDA, EU MDR, and PDMA-approved neurostimulation technology providing safe and effective treatment for moderate to severe obstructive sleep apnea.
See More
Johnson Fistel Investigates Executive Liability for Four Companies
- Shareholder Rights Investigation: Johnson Fistel is investigating potential claims against executives and directors of Charter Communications, Inspire Medical, Firefly Aerospace, and Quantum Corporation for alleged breaches of fiduciary duty, which could lead to corporate governance reforms and fund recovery.
- Charter Communications Allegations: A pending securities class action against Charter alleges that executives failed to disclose the negative impact of the FCC's Affordable Connectivity Program ending on internet customer trends and revenue, resulting in investor losses.
- Inspire Medical Lawsuit: Inspire Medical faces a class action lawsuit alleging that executives overstated demand and readiness for the launch of a new sleep apnea device, failing to disclose significant inventory issues and readiness delays, which led to a reduction in 2025 earnings guidance.
- Firefly Aerospace and Quantum Allegations: Firefly's lawsuit claims executives overstated demand and growth prospects during its IPO, while Quantum faces scrutiny over improper revenue recognition practices, potentially requiring restatement of financial statements, which could undermine investor confidence.
See More
Inspire Medical Systems to Participate in Wells Fargo MedTech Innovation Spotlight
- Management Participation: Inspire Medical Systems' management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026, showcasing its innovative solutions for obstructive sleep apnea, which is expected to attract investor and industry attention.
- Live Presentation Schedule: Inspire is scheduled to present at 10:00 a.m. Eastern Time, with the presentation accessible via a live webcast, enhancing the company's visibility in the medical technology sector to a global audience.
- Replay Availability: A replay of the presentation will be available for two weeks in the Event Archive section of Inspire's investor website, ensuring that investors who cannot attend live can access key information, thereby enhancing information transparency.
- Introduction of Innovative Technology: Inspire's proprietary therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology aimed at providing safe and effective treatment for moderate to severe obstructive sleep apnea patients, further solidifying its market leadership position.
See More
Investment Analysis of Healthcare Device Players
- Alphatec Growth Momentum: Alphatec's revenue for FY 2025 reached approximately $764.2 million, reflecting a 25% increase, despite a net loss of about $143.4 million; however, its net margin improved from -26.5% to -18.8%, indicating growing market acceptance in spine surgery.
- Inspire's Profitability Improvement: Inspire Medical Systems achieved revenue of around $912 million in FY 2025, a 13.6% increase, and successfully transitioned to profitability with a net income of approximately $145.4 million, raising its net margin from 6.7% to 15.9%, solidifying its leadership in advanced respiratory care.
- Competitive Landscape Analysis: Alphatec faces intense competition from giants like Medtronic and Johnson & Johnson, relying on a limited number of suppliers, which may expose it to pricing pressures from hospital consolidations, while Inspire's dependence on its single product makes it vulnerable to shifts in market demand.
- Valuation Comparison: Alphatec has a forward P/E of 25.8x and a P/S ratio of 1.7x, while Inspire's forward P/E is significantly higher at 47.0x with a P/S ratio of 1.3x, highlighting notable differences in market valuations that investors should consider based on their risk preferences.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
Inspire Medical Systems Announces Q2 2026 Earnings Release Date
- Earnings Release Schedule: Inspire Medical Systems will release its financial results for Q2 2026 after market close on August 3, with management hosting a conference call at 5:00 PM ET to discuss the results and recent business developments, ensuring investors stay informed about company updates.
- Conference Call Participation: Investors can access the call via the webcast on the company's Investor Relations page, and those wishing to ask questions must register in advance to receive dial-in details and a unique access code, ensuring connection at least 10 minutes before the call starts.
- Replay Availability: A replay of the call will be available on the company's Investor Relations website approximately two hours after the event, archived for two weeks, allowing investors who could not attend live to catch up on the discussion.
- Company Overview: Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea, with its proprietary Inspire therapy being the first FDA, EU MDR, and PDMA-approved neurostimulation technology providing safe and effective treatment for moderate to severe obstructive sleep apnea.
See More
Johnson Fistel Investigates Executive Liability for Four Companies
- Shareholder Rights Investigation: Johnson Fistel is investigating potential claims against executives and directors of Charter Communications, Inspire Medical, Firefly Aerospace, and Quantum Corporation for alleged breaches of fiduciary duty, which could lead to corporate governance reforms and fund recovery.
- Charter Communications Allegations: A pending securities class action against Charter alleges that executives failed to disclose the negative impact of the FCC's Affordable Connectivity Program ending on internet customer trends and revenue, resulting in investor losses.
- Inspire Medical Lawsuit: Inspire Medical faces a class action lawsuit alleging that executives overstated demand and readiness for the launch of a new sleep apnea device, failing to disclose significant inventory issues and readiness delays, which led to a reduction in 2025 earnings guidance.
- Firefly Aerospace and Quantum Allegations: Firefly's lawsuit claims executives overstated demand and growth prospects during its IPO, while Quantum faces scrutiny over improper revenue recognition practices, potentially requiring restatement of financial statements, which could undermine investor confidence.
See More
Inspire Medical Systems to Participate in Wells Fargo MedTech Innovation Spotlight
- Management Participation: Inspire Medical Systems' management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight on June 26, 2026, showcasing its innovative solutions for obstructive sleep apnea, which is expected to attract investor and industry attention.
- Live Presentation Schedule: Inspire is scheduled to present at 10:00 a.m. Eastern Time, with the presentation accessible via a live webcast, enhancing the company's visibility in the medical technology sector to a global audience.
- Replay Availability: A replay of the presentation will be available for two weeks in the Event Archive section of Inspire's investor website, ensuring that investors who cannot attend live can access key information, thereby enhancing information transparency.
- Introduction of Innovative Technology: Inspire's proprietary therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology aimed at providing safe and effective treatment for moderate to severe obstructive sleep apnea patients, further solidifying its market leadership position.
See More
Investment Analysis of Healthcare Device Players
- Alphatec Growth Momentum: Alphatec's revenue for FY 2025 reached approximately $764.2 million, reflecting a 25% increase, despite a net loss of about $143.4 million; however, its net margin improved from -26.5% to -18.8%, indicating growing market acceptance in spine surgery.
- Inspire's Profitability Improvement: Inspire Medical Systems achieved revenue of around $912 million in FY 2025, a 13.6% increase, and successfully transitioned to profitability with a net income of approximately $145.4 million, raising its net margin from 6.7% to 15.9%, solidifying its leadership in advanced respiratory care.
- Competitive Landscape Analysis: Alphatec faces intense competition from giants like Medtronic and Johnson & Johnson, relying on a limited number of suppliers, which may expose it to pricing pressures from hospital consolidations, while Inspire's dependence on its single product makes it vulnerable to shifts in market demand.
- Valuation Comparison: Alphatec has a forward P/E of 25.8x and a P/S ratio of 1.7x, while Inspire's forward P/E is significantly higher at 47.0x with a P/S ratio of 1.3x, highlighting notable differences in market valuations that investors should consider based on their risk preferences.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
